Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2018 March;60(1) > Minerva Oftalmologica 2018 March;60(1):1-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Minerva Oftalmologica 2018 March;60(1):1-5

DOI: 10.23736/S0026-4903.18.01784-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Oral administration of Casperome® (Boswellia Phytosome®) for the treatment of central serous chorioretinopathy: a pilot study

Fabio MAZZOLANI 1, Stefano TOGNI 2, Federico FRANCESCHI 2, Antonella RIVA 2, Roberto EGGENHÖFFNER 3, Luca GIACOMELLI 3

1 Private Practitioner, Milan, Italy; 2 Indena S.p.A., Milan, Italy; 3 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy


PDF


BACKGROUND: The purpose of this pilot, open-label study was to investigate the effect of Casperome® (Boswellia Phytosome®) on visual acuity and retinal thickness in patients with acute or chronic central serous chorioretinopathy.
METHODS: The study included 10 eyes from 10 patients who completed at least 1-month follow-up period. Casperome® was administered at the dosage of 500 mg daily to patients affected by central serous chorioretinopathy. Macular exudation reduction, as measured by optical coherence tomography, before and after treatment was the primary endpoint. The secondary endpoints were visual acuity stability or improvement. Visual acuity was assessed by ophthalmologic evaluation, and optical coherence tomography was used to measure retinal thickness.
RESULTS: After one month of therapy, the reduction of neuroretinal or retinal pigment epithelium detachment reached significance (P<0.01). After 1 month of therapy, no eyes showed reduction in visual acuity, 70% showed stabilization, and 30% showed improvement.
CONCLUSIONS: These findings, although preliminary, show that Casperome® (Boswellia Phytosome®) may be suitable for the treatment of central serous chorioretinopathy.


KEY WORDS: Boswellia - Central serous chorioretinopathy - Retinal detachment - Retinal pigment epithelium - Macula lutea

top of page